Assay Validation of High Quality Markers for Clinical Studies in Cancer
Funds two years of analytical validation then three of clinical validation for a cancer biomarker assay that already works on human samples.
The National Cancer Institute funds the validation of molecular, cellular and imaging markers and the assays that measure them — for cancer detection, diagnosis, prognosis, monitoring, and predicting response or resistance to treatment, as well as for prevention and control. Pharmacodynamic markers and markers of toxicity are in scope too.
The entry condition is concrete: applicants should alread…
Analytical and clinical validation of molecular, cellular and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring and prediction of response or resistance, plus prevention, control, pharmacodynamic and toxicity markers. Two years analytical, then up to three clinical, including cross-laboratory harmonisation.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up